Safety analysis of the PACS 01 adjuvant trial comparing 6 cycles of FEC 100 to 3 cycles of FEC 100 followed by 3 cycles of docetaxel Taxotere® for node positive breast cancer

被引：0

作者：

Roche, H ^{[1
]}

Spielmann, M ^{[1
]}

Fumoleau, P ^{[1
]}

Canon, JL ^{[1
]}

Bravo, P ^{[1
]}

Orfreuvre, H ^{[1
]}

Piot, G ^{[1
]}

Kerbrat, P ^{[1
]}

Serin, D ^{[1
]}

Viens, P ^{[1
]}

Geneve, J ^{[1
]}

Asselain, B ^{[1
]}

机构：

[1] Inst Claudius Regaud, Toulouse, France

来源：

BREAST CANCER RESEARCH AND TREATMENT | 2003年 / 82卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

144

引用

页码：S32 / S32

页数：1

共 50 条

[1] Five years analysis of the PACS 01 trial:: 6 cycles of FEC100 vs 3 cycles of FECI00 followed by 3 cycles of docetaxel (D) for the adjuvant treatment of node positive breast cancer
Roché, H
Fumoleau, P
Spielmann, M
Canon, JL
Delozier, T
Kerbrat, P
Serin, D
Lortholary, A
de Ghislain, C
Viens, P
Bergerat, JP
Genève, J
Martin, AL
Asselain, B
[J]. BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S16 - S16
[2] Preliminary safety data of the EORTC 10994/BIG 00-01 neoadjuvant trial comparing 3 cycles of docetaxel followed by 3 cycles of epirubicin-docetaxel versus 6 cycles of FEC 100 in patients with locally advanced/inflammatory or large operable breast cancer.
Karina, M.
Bogaerts, J.
Piccart, M.
Mauriac, L.
Campone, M.
Tubiana-Hulin, M.
Petit, T.
Rouanet, P.
Jassem, J.
Cufer, T.
Blot, E.
Abadie-Lacourtoisie, S.
Zaman, K.
Amaral, N.
Cameron, D.
Bergh, J.
Bonnefoi, H.
[J]. BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S146 - S147
[3] A phase III adjuvant randomised trial of 6 cycles of 5-fluorouracil-epirubicine-cyclophosphamide (FEC100) versus 4 FEC 100 followed by 4 Taxol (FEC-T) in node positive breast cancer patients (Trial B2000)
Delbaldo, C.
Serin, D.
Mousseau, M.
Greget, S.
Audhuy, B.
Priou, F.
Berdah, J. F.
Teissier, E.
Laplaige, P.
Zelek, L.
Quinaux, E.
Buyse, M.
Piedbois, P.
[J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 (01) : 23 - 30
[4] A Phase III Adjuvant Randomized Trial of 6 Cycles of 5-Fluorouracil - Epirubicine-Cyclophosphamide (FEC100) Versus 4 FEC 100 Followed by 4 Taxol (FEC-T) in Node Positive Breast Cancer Patients (Trial B2000)
Delbaldo, C.
Serin, D.
Mousseau, M.
Greget, S.
Audhuy, B.
Priou, F.
Berdah, J-F
Teissier, E.
Quinaux, E.
Piedbois, P.
[J]. CANCER RESEARCH, 2010, 70
[5] Safety analysis from PACS 04 -: A phase III trial comparing 6 cycles of FEC100 with 6 cycles of ET75 for node-positive early breast cancer patients, followed by sequential trastuzumab in HER2+ patients:: Preliminary results.
Spielmann, M.
Roché, H.
Delozier, T.
Romieu, G.
Bourgeois, H.
Serin, D.
Canon, J.
Asselain, B.
Roca, L.
Genève, J.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 35S - 35S
[6] A randomized phase Ill trial of neoadjuvant sequential chemotherapy with 4 cycles of adriamycin plus cyclophosphamide followed by 4 cycles of docetaxel (AC4-D4) versus shorter 3 cycles of FEC followed by 3 cycles of docetaxel (FEC3-D3) in node-positive breast cancer (Neo-Shorter): First report of efficacy & toxicity profile
Kim, J. E.
Ahn, J-H
Jung, K. H.
Lee, H. J.
Gong, G-Y
Lee, E-M
Ha, E. J.
Son, B-H
Ahn, S-H
Ahn, S. D.
Kim, H-H
Shin, H. J.
Kim, S-B
[J]. CANCER RESEARCH, 2016, 76
[7] Randomized phase III trial of a neoadjuvant regimen of four cycles of adriamycin plus cyclophosphamide followed by four cycles of docetaxel (AC4-D4) versus a shorter treatment of three cycles of FEC followed by three cycles of docetaxel (FEC3-D3) in node-positive breast cancer (Neo-shorter; NCT02001506)
Inhwan Hwang
Jeong Eun Kim
Jae Ho Jeong
Jin-Hee Ahn
Kyung Hae Jung
Byung Ho Son
Hak Hee Kim
Junyoung Shin
Hee Jin Lee
Gyungyub Gong
Sung-Bae Kim
[J]. Breast Cancer Research and Treatment, 2023, 201 : 193 - 204
[8] Randomized phase III trial of a neoadjuvant regimen of four cycles of adriamycin plus cyclophosphamide followed by four cycles of docetaxel (AC4-D4) versus a shorter treatment of three cycles of FEC followed by three cycles of docetaxel (FEC3-D3) in node-positive breast cancer (Neo-shorter; NCT02001506)
Hwang, Inhwan
Kim, Jeong Eun
Jeong, Jae Ho
Ahn, Jin-Hee
Jung, Kyung Hae
Son, Byung Ho
Kim, Hak Hee
Shin, Junyoung
Lee, Hee Jin
Gong, Gyungyub
Kim, Sung-Bae
[J]. BREAST CANCER RESEARCH AND TREATMENT, 2023, 201 (02) : 193 - 204
[9] Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology)
Geyer, Charles E., Jr.
Bandos, Hanna
Rastogi, Priya
Jacobs, Samuel A.
Robidoux, Andre
Fehrenbacher, Louis
Ward, Patrick J.
Polikoff, Jonathan
Brufsky, Adam M.
Provencher, Louise
Paterson, Alexander H. G.
Hamm, John T.
Carolla, Robert L.
Baez-Diaz, Luis
Julian, Thomas B.
Swain, Sandra M.
Mamounas, Eleftherios P.
Wolmark, Norman
[J]. BREAST CANCER RESEARCH AND TREATMENT, 2022, 193 (03) : 555 - 564
[10] Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology)
Charles E. Geyer
Hanna Bandos
Priya Rastogi
Samuel A. Jacobs
André Robidoux
Louis Fehrenbacher
Patrick J. Ward
Jonathan Polikoff
Adam M. Brufsky
Louise Provencher
Alexander H. G. Paterson
John T. Hamm
Robert L. Carolla
Luis Baez-Diaz
Thomas B. Julian
Sandra M. Swain
Eleftherios P. Mamounas
Norman Wolmark
[J]. Breast Cancer Research and Treatment, 2022, 193 : 555 - 564

← 1 2 3 4 5 →